Treatment of anxiety disorders in clinical practice: a critical overview of recent systematic evidence by Mangolini, Vitor Iglesias et al.
Treatment of anxiety disorders in clinical practice:
a critical overview of recent systematic evidence
Vitor Iglesias Mangolini0000-0000-0000-0000 ,I,II Laura Helena Andrade0000-0000-0000-0000 ,II Francisco Lotufo-Neto0000-0000-0000-0000 ,II Yuan-Pang Wang0000-0000-0000-0000 II,*
I Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR. IIDepartamento de Psiquiatria, Instituto de Psiquiatria, LIM-23, Hospital das
Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Mangolini VI, Andrade LH, Lotufo-Neto F, Wang YP. Treatment of anxiety disorders in clinical practice: a critical overview of recent systematic evidence.
Clinics. 2019;74:e1316
*Corresponding author. E-mail: gnap_inbox@hotmail.com
The aim of this study was to review emerging evidence of novel treatments for anxiety disorders. We searched
PubMed and EMBASE for evidence-based therapeutic alternatives for anxiety disorders in adults, covering the
past five years. Eligible articles were systematic reviews (with or without meta-analysis), which evaluated
treatment effectiveness of either nonbiological or biological interventions for anxiety disorders. Retrieved
articles were summarized as an overview. We assessed methods, quality of evidence, and risk of bias of the
articles. Nineteen systematic reviews provided information on almost 88 thousand participants, distributed
across 811 clinical trials. Regarding the interventions, 11 reviews investigated psychological or nonbiological
treatments; 5, pharmacological or biological; and 3, more than one type of active intervention. Computer-
delivered psychological interventions were helpful for treating anxiety of low-to-moderate intensity, but the
therapist-oriented approaches had greater results. Recommendations for regular exercise, mindfulness, yoga,
and safety behaviors were applicable to anxiety. Transcranial magnetic stimulation, medication augmentation,
and new pharmacological agents (vortioxetine) presented inconclusive benefits in patients with anxiety
disorders who presented partial responses or refractoriness to standard treatment. New treatment options for
anxiety disorders should only be provided to the community after a thorough examination of their efficacy.
KEYWORDS: Anxiety Disorders; Therapeutics; Psychotherapy; Psychopharmacology; Systematic Review.
’ INTRODUCTION
According to the World Health Organization (1), anxiety
disorders are burdensome ‘‘common mental disorders’’ to
communities. These prevalent disorders are not communic-
able and affect approximately one in every five individuals
of the world population (2-4). This figure represents the largest
share of the prevalence of all mental disorders, whereas severe
psychotic and bipolar disorders affect only between 1% and 2%
of the population. In an upper-middle income country such as
Brazil, the 12-month prevalence of anxiety disorders has been
estimated as 19.9% among the dwellers of a large metropolitan
area (5).
The cost of anxiety disorders to the working world is
remarkable, corresponding to a total loss of 74.4 billion Euros
in 2010 (3). The global burden of anxiety disorders represents
10.4% of years lived with adjusted disability (DALY) of
mental disorders, reaching 26,800,000 DALYs (2). Despite the
societal burden of this morbidity, only approximately one in
five patients diagnosed with anxiety disorder obtain access
to treatment (6,7).
Anxiety disorders present an early onset, even during child-
hood. Their enduring waxing and waning course deeply
affects patients’ functionality and interpersonal relationships
throughout the lifespan (8). Most pathological anxiety (specific
phobias, social anxiety, generalized anxiety, separation anxiety,
obsessive-compulsive, and panic disorder) is underrecognized,
and patients seek treatment in outpatient settings, either in
medical or specialized mental health-care contexts (7). How-
ever, anxiety disorders receive less attention from clinicians
when compared with major mental disorders, such as psy-
chotic conditions and substance use disorders that require
hospitalization. Moreover, anxiety is less reported in the
media than depression and suicide attempts, which reduces
the help-seeking behaviors of patients suffering from anxiety.
Figure 1 summarizes key uncontroversial characteristics and
clinical practices regarding the treatment of anxiety disorders
(9-11). Most experts advocate either psychotherapy and/or
pharmacotherapy for alleviating or controlling symptoms of
anxiety. The combination of psychological treatment with
psychotropic drugs is recommended for patients with severe
cases of disabling anxiety.
Traditionally, several talk therapies are subsumed as
techniques of psychological treatment and have been
recommended to handle different degrees of anxiety (11).
Well-accepted but not always efficacious modalities of
psychotherapy vary from psychoanalytic, cognitive-behavioral,
interpersonal, supportive, and group therapy to brief therapy.DOI: 10.6061/clinics/2019/e1316
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The literature on cognitive-behavioral therapy (CBT) has
established a foundation of effectiveness evidence for different
anxiety disorders (9,11), but new therapeutic modalities
should have their benefit assessed. In addition, the existing
number of mental health professionals is insufficient for the
number of patients who need treatment (6). Thus, a more
accessible and cost-effective modality of psychotherapeutic
treatment for anxiety should be offered to the community.
More than six decades ago, since the synthesis of chlordia-
zepoxide in 1957 (12), benzodiazepine medications have
become the main class of pharmacological agents for the
treatment of anxiety disorders. The introduction of these
anxiolytic medicines received an immediate welcome from
medical professionals and anxiety-laden patients. None-
theless, the risk of side effects, a withdrawal syndrome and
dependence on benzodiazepines have led patients in need of
treatment to seek less harmful therapeutic substitutes, which
do not always have proven efficacy. Accepted psychophar-
macological medicines include antidepressants, buspirone,
beta-blockers, and antipsychotics. Their efficacy has been
demonstrated in well-designed clinical trials and abridged in
comprehensive reviews (10). The combined use of psycho-
logical treatment with psychotropic drugs is more commonly
recommended for cases of anxiety of greater severity and
disability (11).
Many complementary and alternative treatments of mild
forms of anxiety have gained popularity because of their
alleged harmlessness. Examples of complementary treat-
ment include aromatherapy, acupuncture, herbal medicine,
homeopathy, massage therapy, yoga, mindfulness, exercise
practice, relaxation, etc. (6,7). The diversity of modalities that
a patient is exposed to varies in accordance with the gui-
dance of the therapist, use of an active substance, and body
manipulation. Exhaustive classification is difficult. While
mental health professionals support the adjunctive addition
of these modalities, for anxiety disorders in particular, the
exclusive use of alternative therapies as a surrogate to well-
established forms of treatment should be avoided (11). Most
complementary and alternative treatments lack evidence
of effectiveness. It is possible that a placebo effect and a
good therapeutic relationship between the practitioner and
patients underlie their positive outcomes.
There are a wealth of treatments devoted to controlling the
symptoms of anxiety, but nonconventional and newer psy-
chotherapeutic treatments and pharmacological agents are
propagated without an acceptable confirmation of benefit.
In the present review, we searched for recent evidence of
nonbiological (psychological) and biological (pharmacologi-
cal) modalities for treating anxiety disorders. The compre-
hensive summary of treatment advances is organized for a
professional who is in training or is not a specialist in mental
health to supplement existing modalities. Complementary
and alternative treatments with evidence of effectiveness are
explored herein under the group of nonbiological therapies.
Additionally, high-quality systematic reviews (SRs) were
chosen over sparse clinical trials in need of additional
replication. The usefulness and public health importance of
the treatment of anxiety are subsequently discussed.
’ METHODS
Our research question was to update the evidence on
recent interventions for the broad category of anxiety dis-
orders. In the present study, the PICO components included
adult Patients with a clinical diagnosis of ‘‘anxiety disorder’’,
who were subjected to one or more Interventions (either
biological or nonbiological). The intervention must be Com-
pared with a placebo or standard therapeutics for assessing
the treatment Outcomes.
We searched for articles in the PubMed and EMBASE
databases on the treatment of anxiety disorders. The key
Medical Subject Heading (MeSH) terms were ‘‘anxiety
Figure 1 - What we already know about the treatment of anxiety disorders (9,10,11).
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disorders’’ AND ‘‘treatment’’. The retrieved articles were
displayed in the Mendeley platform and filtered in accor-
dance with the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) guidelines (13). The
arguments of the search strategy can be found in Supple-
mentary Table 1.
For inclusion, the article type must be an SR, with or with-
out meta-analysis, of clinical trials involving adult patients
diagnosed with an anxiety disorder. Rigorous randomized
clinical trials (RCTs) compared with placebo or active inter-
ventions were considered the highest evidence of effective-
ness. Those articles wherein participants encompassed a
mixed sample of adults and children were not eligible unless
separate data were comprehensively presented. Only articles
published in the last 5 years, from January 2013 through
September 31, 2018, were considered appropriate. There was
no language restriction regarding published articles.
After hand searching, by reading the reference list of retained
articles and chapters, and contact with potential authors, we
identified two additional articles (14,15).
Regarding exclusion criteria, articles containing primary
data, duplicate SR or animal models of anxiety were not
eligible. Posttraumatic stress disorder was not considered in
the present overview because this disorder is not covered
under the MeSH term ‘‘anxiety disorders’’ and is no longer
listed in the DSM-5 chapter of anxiety disorders (16). In
contrast, while the DSM-5 describes obsessive-compulsive
disorders in a separate chapter, this group of disorders is still
listed under the MeSH entry of anxiety disorders. Further-
more, treatments on the cooccurrence of anxiety disorders in
a specialized medical context (e.g., heart disease, endocrino-
logical, neurological conditions, pain clinics, etc.) were elimi-
nated. Observational studies, case reports, comments,
practice guidelines and editorials on therapeutic modalities
were also excluded from this overview. Two authors (V.I.M.
and Y.P.W.) decided the final list of selected articles.
Study method
Often, an individual SR cannot address all proposed
interventions for the same problem. Recent advances in the
treatment of anxiety disorders are updated in the current
study with the methodological framework of a systematic
overview (17). Accordingly, this type of meta-review is a
relatively new method to achieve a high level of evidence,
wherein systematic evidence gathered from more than one
SR or meta-analysis is examined in a single accessible work,
also known as a ‘‘systematic review of systematic reviews’’
(17). The compilation of evidence synthesizes different inter-
ventions for the same problem or condition on different
outcomes for different conditions, problems or populations.
The ultimate result provides a global summary of the avai-
lable evidence rather than providing data synthesis (17,18).
Thus, an overview aims to examine the highest level of
evidence and provide a global account of findings (19). This
type of review has the advantage of rapidly combining rele-
vant data to make evidence-based clinical decisions. Stake-
holders, managers and health professionals can appraise
multiple high-quality studies in a single general summary of
a particular question.
The quality of the retained review articles was assessed in
accordance with ‘‘A MeaSurement Tool to Assess systematic
Reviews’’ (AMSTAR version 2) (20). The 16-item AMSTAR
checklist (https://amstar.ca) represents a critical appraisal of
the quality of SRs, covering different aspects related to study
planning and conduct, such as the research question, review
protocol, selection of study design, search strategy, explicit
inclusion and exclusion criteria, risk assessment of bias, and
publication bias. For the interpretation of detected weak-
nesses in critical and noncritical items, the AMSTAR recom-
mends a categorization of the overall confidence in the
results of the SR as follows: high, moderate, low, and criti-
cally low. The assessment of the risk of bias of an SR was
supplemented with the Risk Of Bias In Systematic review
(ROBIS) guidelines (21), which allows classification of the
existence of bias as low, high or unclear. All rating disagree-
ments were reconciled during discussion meetings.
’ RESULTS
Figure 2 shows the PRISMA flow diagram of the retrieved
articles in this overview. From the initial 96 review articles
published between 2013 and 2018, 92 nonduplicated articles
were screened for title and abstract. Most studies (k=66) were
removed because the participants presented anxiety symp-
toms in the context of medical diseases or were nonadults.
After eliminating ineligible articles that fell outside the topic
of overview, 26 articles were retained for full-text reading.
An additional 7 articles were excluded because 6 did not
present an SR and 1 did not contain recent data. The reasons
for article exclusion can be found in Supplementary Table 2.
Accordingly, 19 recent SRs were included in the final list for
the qualitative synthesis. Of these studies, 3 did not estimate
the pooled effect size of the outcomes through a meta-
analytical quantitative synthesis (22-24).
Table 1 summarizes the main characteristics and methods
of the 19 retained studies. From these articles, 11 referred to
nonbiological treatments for anxiety (media- or internet-
assisted CBT therapy, brief psychodynamic therapy, Morita
therapy, effects of safety behavior, practices of exercise,
mindfulness, and yoga, etc.), 5 referred to biological treat-
ments for anxiety (repetitive transcranial magnetic stimula-
tion and pharmacotherapy), and 3 referred to multimodal
combined treatment comparisons (stepped care vs. care-as-
usual and comparison of multiple treatments). All articles
were published in English, and the investigators had
searched for relevant articles in at least two databases.
Although our search was restricted between 2013 and 2018,
the majority of retained SRs covered the previous period,
from the database inception date up to 2017.
Across the SRs, there were a total of 811 RCTs (range: 2–
234 RCTs), with an included total of 87,773 adult participants
(range: 40–37,333 patients). Three SRs (15,35,36) included
over 10,000 participants, 6 SRs (25-29,37) between 9,999 and
1,000 participants, 8 SRs less than 1,000 participants (22,23,
30-34,38), and 2 SRs did not report the exact number due to
the mixture of adult and underage participants (14,24). Most
SRs (k=14) did not report or summarize the percentage of
female participants. The other 5 SRs (25,28,30,33,38) indi-
cated the proportion of women (range: 55.5%-67.7%).
Regarding the diagnosis of the participants, the majority of
studies investigated the disorder either under a generic
diagnostic label of anxiety disorders or common mental
disorders. SRs evaluated the effects of specific interventions
in social anxiety (14,15,23,24,35), panic (14,15,33), general-
ized anxiety (14,15), and obsessive-compulsive disorder (36).
All articles described the exclusion of ineligible partici-
pants (e.g., posttraumatic stress or acute stress disorders,
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depressive disorders, comorbid physical illnesses, psychotic
disorders, nonappropriate psychiatric diagnoses, underage
participants, etc.) and inappropriate studies (e.g., small
sample size or case studies, sampling or statistical issues,
unsuitable interventions, etc.).
The Cochrane’s Collaboration Tool to Assess Risk of Bias
was the most commonly used instrument (k=14) to evaluate
the risk of bias in each individual SR. Two SRs (14,15) used
the Scottish Intercollegiate Guidelines Network (SIGN)
checklist, and an additional 3 SRs (24,36,37) did not assess
the risk of bias.
Evidence of treatment efficacy
Regarding the results of nonbiological or psychological
treatments, 5 SRs evaluated computer-delivered psychologi-
cal therapy (14,15,25,26,28). The evidence suggested that the
online therapeutic approach is a feasible and beneficial
treatment option. However, face-to-face therapist-guided
therapy seemed to be clinically superior when compared
with the computer-guided approach. Additionally, the
benefit widely varied in accordance with the type and
characteristics of anxiety disorder.
A meta-analysis (27) reported that short-term psychody-
namic psychotherapies appear to show a reduction in
anxiety symptoms in the short and medium term. The SR
of Morita therapy–a specific type of self-acceptance method–
showed data of limited applicability because all eligible
studies were conducted in China, restricting the utility of
conclusions in Western countries (30).
Three SRs (23,24,35) had specifically included patients
with social anxiety. Mindfulness and acceptance-based
treatment (23) was a viable option, but the level of evidence
was limited due to the risk of bias. For social anxiety, limited
evidence suggested that reductions in the use of safety
behaviors or avoidance were related to a better CBT outcome
(24). In addition, symptomatic decreases in social anxiety
predicted reduced safety-behavior use over the course of
treatment.
Two SRs (22,31) evaluated the benefit of exercise in
reducing anxiety symptoms. Both studies indicated that the
exercise practice was effective, regardless of the type and
intensity of physical activity. However, exercise alone was
less effective than standard antidepressant treatment (15).
Although the effect of yoga on anxiety disorder was
considered a safe intervention, the gathered evidence for its
effects was inconclusive (32). Main critiques referred to the
variety of diagnoses, heterogeneity of interventions, poten-
tial bias of low-quality studies, and lack of comparison to
other treatments.
Regarding biological or pharmacological treatments, one
meta-analysis (33) assessed transcranial magnetic stimula-
tion in 40 participants with panic disorder. However, there
was insufficient evidence to draw any solid conclusion about
its efficacy because of the small sample size and significant
methodological flaws. In addition to sampling issues
(randomization and allocation concealment), the evidence
in the 2 RCTs reviewed was of very low quality.
For pharmacological treatments, there was evidence of
low-to-moderate quality for the use of selective serotonin
reuptake inhibitors (SSRIs) for social anxiety (35). However,
their tolerability seemed to be lower than placebo. The
augmentation strategy did not appear to be beneficial in
patients with treatment-resistant anxiety disorders, e.g.,Ta
b
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generalized anxiety, social anxiety, and panic disorder (34). In
a comparison of the effects of second-generation antidepres-
sants for obsessive-compulsive vs. generalized anxiety dis-
order, panic disorder, posttraumatic stress disorder, and
social anxiety disorder (in over 15,000 participants), an SR
(36) found that pharmacotherapy presented a smaller overall
change score than placebo for those five categories of anxiety
disorders. Finally, an SR of incipient trials of vortioxetine
supported its use for anxiety (37), but more long-term
placebo-controlled trials are warranted.
The SR on multimodal combined treatments reviewed 10
RCTs and compared the package of stepped care versus care-
as-usual (38). The authors concluded that the stepped-care
model of treatment of anxiety disorders appeared to be
superior than care-as-usual in terms of efficacy and cost-
effectiveness. As a consequence, stepped care can reduce the
burden on service providers and increase availability. In a
comprehensive SR on multiple treatment modalities with
over 37 thousand participants (15), the average pre-post
effect sizes of medications were more effective than psycho-
therapies. In general, the effects of psychotherapies did not
differ from placebo pills. Surprisingly, not only psychother-
apy but also medications and, to a lesser extent, placebo
conditions have shown similar enduring effects in the
improvement of anxiety disorders (14). Nevertheless, long-
lasting treatment effects observed in the follow-up period
were superimposed in patients receiving different therapeu-
tics at the same time.
Figure 2 - Flow diagram according to PRISMA (www.prisma-statement.org) for identifying eligible articles (k=number of studies).
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Quality of evidence
Using the AMSTAR guideline, Table 2 presents the assess-
ment of the quality of each individual SR. The overall confi-
dence of each study was rated after evaluating critical and
noncritical items of the AMSTAR. Several SRs (k=6) were
rated as high quality (25,27,28,30,33,35); 3, as moderate
(23,26,31); 7, as low (14,15,22,29,31,34,38); and 3, as critically
low (24,36,37). All six reliable articles (AMSTAR high quality
and ROBIS low risk of bias) were published in the Cochrane
Database of Systematic Reviews and rigorously adhered to
the guidelines of the Cochrane’s Collaboration Tool to Assess
Risk of Bias.
Most of the studies clearly described the planning phase of
the SR, which included explicit research questions, selection
criteria, data extraction and assessment of the risk of bias.
Not all studies previously registered a protocol before perfor-
ming the SR. Only 3 studies reported the source of funding of
the included studies (25,30,35). During the data interpreta-
tion, the most frequent problems were no clear discussion of
the individual bias of selected studies (k=9) and did not
account for publication bias (k=5). Notably, the 3 SRs that did
not subject the RCTs to a meta-analytical synthesis also
presented several shortcomings that critically affected the
quality of the articles (e.g., omission of excluded studies,
nonevidence-based discussion of results, and no prior pro-
tocol registration).
The risk of bias was rated with the aid of ROBIS (Table 2),
with 8 SRs having low risk (25-28,30,31,33,35); 8, uncertain
risk (14,15,22,23,29,31,34,38); and 3, high risk (24,36,37).
There was a rough agreement between the quality of an SR
(AMSTAR) and the risk of bias (ROBIS). Unsurprisingly,
while most high-to-moderate quality studies presented a low
risk of bias, all three studies of critically low quality also
presented a high risk of bias (24,36,37). In Supplementary
Table 3, detailed ROBIS ratings for each retained study are
shown.
’ DISCUSSION
The current overview summarized the evidence of the
efficacy of emerging treatment options in the last 5 years for
adult patients with an anxiety disorder. The conclusions of 19
relevant SRs were synthesized and combined, for a total of
87,773 participants distributed in 811 RCTs. There was great
cross-study heterogeneity in terms of the research question,
target disorder, type of intervention, methodology, number
of included RCTs, sample size of participants, and measured
outcomes. Most studies investigated the benefit of different
forms of psychotherapy and physical activity. In terms of
biological treatments, no great evidence of effectiveness was
found for transcranial magnetic stimulation and pharmaco-
logical strategies (drug augmentation or novel agents).
Newer treatments for anxiety disorders are highly relevant
because the majority of cases are underdetected and
undertreated within health-care systems, even in economic-
ally developed countries (14). Most anxious patients world-
wide do not receive standard treatment with combined
psychotherapy and pharmacological agents in terms of
adherence, frequency, and adequacy (6,9,11). Consequently,
untreated patients with these disorders chronically endure
these symptoms, which are associated with severe impair-
ments and restrictions in role functioning and disabilities (6).
The present overview of SRs presented a resynthesis of
existing data to allow better choices among emerging
interventions for anxiety disorders. This rapid review of
high-quality evidence can be of great clinical utility for
decision-makers and public health administrators. Until
more robust evidence is published, the initial enthusiasm
for many proposed anti-anxiety alternatives has shrunk.
Meanwhile, the evidence of many therapeutic alternatives
should be watchfully disseminated to the community.
Interpretation and implications
From the present overview, there is convincing evidence
that computer-delivered psychological treatment is helpful
for the treatment of distressing anxiety of different intensities
(25). However, the therapist-oriented CBT approach has
yielded better results (25,28). Along similar lines, short-term
psychodynamic psychotherapies have shown consistent
gains, but larger studies with specific anxiety disorders are
warranted (27). From a public health standpoint, computer-
assisted treatment is not readily accessible in several non-
developed countries, but this strategy can benefit those
patients living in distant places or unwilling to start formal
psychotherapy. Furthermore, sharing a single computer device
and delivering brief psychotherapy are cost-effective for a
community (40).
There is evidence of moderate-to-high quality suggesting
that the online approach may be favorable and more effica-
cious than a wait list, informational pamphlets, or online
discussion groups (25). Therefore, the self-help approach can
be recommended as the first step in the treatment of mild
anxiety disorders, but the short- and long-term effects of
computer-delivered interventions and brief psychotherapies
need to be fully established.
Although the SR of Morita therapy was of high quality
and free of the risk of bias, its applicability is limited (30). All
7 RCTs of Morita therapy were conducted in Eastern countries,
curbing its generalizability to Western populations (41).
Two promising high-quality SRs still required additional
evidence of effectiveness with additional RCTs; pioneering
transcranial magnetic stimulation (33) and the use of SSRIs in
social anxiety (35) have shown insufficient evidence of
efficacy. The SR of transcranial stimulation studies was
conducted on 2 RCTs with 40 patients with panic disorder.
Therefore, further trials with a larger sample are needed. The
use of SSRIs in social anxiety has shown low-to-moderate
evidence of efficacy and was less tolerable than placebo (35).
These two strategies can be advised for specific anxiety
disorders and those patients who presented partial response
or refractoriness to standard treatment (35,42-45). In a further
meta-analysis based on weekly outcome data (46), the treat-
ment benefits of SSRIs and serotonin norepinephrine reup-
take inhibitors (SNRIs) were shown for social anxiety. Higher
doses of SSRIs, but not SNRIs, were associated with symp-
tomatic improvement and treatment response. However, the
potential risk of intolerance may surpass the benefit to the
patients (46).
With an ever-growing list of psychotropic compounds
showing apparent anxiolytic properties, current pharmaco-
logical options for treating clinical anxiety are broad and
vast. Existing SRs (14,15) demonstrate that the magnitude of
efficacy for most anxiolytic agents compared with placebo
was superior. However, the likelihood of symptomatic remis-
sion after a pharmacological trial remains largely unknown.
Progress in neuroscience and neurophysiology may unravel
the pathways of therapeutic responsiveness.
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Thus, the generalizability of emerging treatments, e.g.,
transcranial stimulation and newer pharmacological strate-
gies, is limited due to sampling issues, methodological flaws,
and applicability in specific anxiety disorders. These poten-
tial interventions might not be available to all consumers,
and therefore, larger and more pragmatic RCTs are needed to
evaluate and maximize the benefits of available interventions
(42-45).
Behavioral recommendations of regular exercise (22,31),
mindfulness practice (23), and yoga (32) have also been
shown to be beneficial for improving anxiety symptoms.
However, these SRs were of low-to-moderate quality and
vulnerable to the risk of bias. The universal campaign of
healthy activities might be recommended as an adjunctive
treatment to standard treatment and a cost-effective strategy
in regions where there is a shortage of qualified thera-
pists. Nonetheless, these practices were less effective when
compared with antidepressant pharmacotherapy (15). Even
without sufficient evidence of effectiveness, these nonstan-
dard treatments seem to be safe, inexpensive and can be
easily implemented with preventive purposes to community
dwellers (47).
Although methodological questions remain before its
broad implementation can be supported, the personalized
therapist-guided CBT approach is the most recommended
nonpharmacological treatment for anxiety (48). Similarly,
while the practice of physical activities is safe and helpful,
traditional antidepressant treatment presents better results
(9,14). One unanswered question refers to the potential
adverse effects of the nonsupervised use of computer-
assisted therapies and exercise practice. These concerns need
to be refined in future RCTs.
Among those patients receiving long-term treatments with
partial response or refractoriness, it is possible that novel
strategies can enhance and sustain the improvements in
anxiety. Hence, there is a large amount of room for amend-
ments to treatment plans (34-38), at least for specific and
severe anxiety disorders. Future studies should include
stratification of anxiety by severity status and persistence
to characterize the dose-response relationship of interven-
tions and the combined efficacy of psychotherapy and
pharmacotherapy in treating anxiety disorders, in addition
to rule out potential confounding factors that affect treatment
effectiveness (49,50).
Some SRs were untrustworthy due to their low quality and
serious biases. For example, the impact of safety behaviors
in social anxiety remains unknown (24), as well as the redu-
ced response to placebo and antidepressants in obsessive-
compulsive disorders (36) and the benefit of vortioxetine for
the treatment of anxiety disorders (37). In general, the most
common shortcomings were the lack of a published protocol,
unclear study selection, inadequate search strategy, lack of
explicit inclusion and exclusion criteria, nonexhaustive
assessment of bias, invalid interpretation, and no report of
publication bias. Consequently, these topics require urgent
clarification, using a more stringent methodology and longer
follow-up to answer the proposed research question.
Limitations
The heterogeneous interventions reported in these SRs
with diverse outcomes preclude conducting a quantitative
meta-analytical synthesis as an umbrella review (17-19,39).
However, the present systematic overview has assessed the
risk of bias of each individual SR, and it is secure to claim
that most of the evidence reported herein was trustworthy.
The search for recent SRs on the treatment of anxiety
disorders has identified main review articles, but some gray
literature might have been missed. Although the studies in
the Cochrane library were covered in PubMed and EMBASE,
ongoing SRs must be finalized to draw solid conclusions.
Along these lines, the Cochrane register and PROSPERO
data were not scanned to detect other SRs. However, preli-
minary findings or unpublished SRs should not be integrated
into the present overview. It is possibly that a selection bias
of new treatment alternatives for specific anxiety disorders
occurred at the time of the search. The potential omission of
ongoing RCTs cannot be ruled out, but untrustworthy
or partial evidence should not be taken as high-quality
information.
A potential bias of overview studies is overlap in the
retrieved articles or the use of the same primary study in
multiple included SRs (51,52). In the present review, most of
the treatment modalities were addressed by only one inclu-
ded SR, which probably reduced the probability of overlap
across those studies. However, there were two interventions
that were addressed by multiple studies: media-delivered
psychotherapy and physical exercises. Five SRs examined
media-delivered psychotherapy, with a total of 463 RCTs
included in the reviews. It is possible that overlap occurred
across these SRs, and subtle differences exist regarding the
sample, scientific question, comparator, and inclusion of
therapist. Therefore, we cannot rule out the possibility of
overlapping articles, and the strength of the conclusion about
media-delivered psychotherapy should be softened. In
contrast, in the two existing SRs on physical exercises, we
found 16.7% overlap across the included RCTs. In addition,
the overall quality of the articles on physical exercise was
low-to-moderate according to the AMSTAR analysis. This
fact likely endorses the lower efficacy of physical exercises
than standard care.
The covered period of five years may have not included all
published studies before 2013. Nevertheless, these recent
articles have offered updated coverage of previous studies
conducted more than five years ago. Because our primary
goal was to condense recent advances on the evidence-based
therapeutics for anxiety, well-known modalities were outside
the scope of the present review. Notwithstanding, two com-
prehensive meta-analyses conducted by Bandelow’s group
(14,15) provided a broad summary of existing evidence on
treatments for anxiety disorders, as well as the comparative
enduring effect of psychological treatments and efficacy of
treatments.
Trials with negative results might remain unpublished,
and practitioners continue advising off-label use without any
evidence of effectiveness or benefit. This publication bias of
the file drawer effect cannot be ruled out. Small study bias
and excluded participants may have affected the scientific
soundness of the conclusions. For example, repetitive trans-
cranial stimulation still requires a larger sample (42-45), and
Morita therapy should be investigated in Western countries
and regions in different stages of development (41).
’ CONCLUSIONS
The present overview of recent treatment trends for
anxiety disorders provides an account of the evolving
directions to pursue, in terms of state-of-art scientific
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development. Effective and older treatments should be
enhanced with technological innovations such as computer-
based CBT and supplemented by adjunctive physical acti-
vities. New biological or pharmacological treatment mod-
alities for anxiety disorders still need further evidence of
usefulness. Thus, all treatments for anxiety disorders with
proven effectiveness should be continuously investigated to
make them available to the community.
The worldwide burden of anxiety disorders is high. There-
fore, obtaining access to reliable health-care services is a
bonafide and essential need in a globalized world. However,
direct-to-consumer universal access to emerging treatments
for anxiety should be recommended only after demonstra-
tion of robust evidence of efficacy.
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’ APPENDIX
Supplementary Table 1 - Search Strategies
SEARCH
DATABASE #1
PubMed
 Article types: Review
 Time period covered: Last 5 years
 Language: English, Portuguese and Spanish
 Age: Adults 19+
 Species: Humans
Search strategy:
anxiety disorders[Title/Abstract] AND treatment[Title/Abstract] AND (Review[ptyp] AND ‘‘2013/01/01’’[PDAT] : ‘‘2018/
12/31’’[PDAT] AND ‘‘humans’’[MeSH Terms] AND (English[lang] OR Portuguese[lang] OR Spanish[lang]) AND ‘‘adult’’
[MeSH Terms])
# of articles retrieved: 72
DATABASE #2
EMBASE
 Article types: Review
 Time period covered: 2013-2018
 Language: English, Portuguese and Spanish
 Age: Adults
 Species: Humans
Search strategy:
‘anxiety disorder’:ab,ti AND ‘treatment’:ab,ti AND [review]/lim AND ([english]/lim OR [portuguese]/lim OR [spanish]/
lim) AND [adult]/lim AND [humans]/lim AND [2013-2018]/py
# of articles retrieved: 22
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Supplementary Table 2 - List of excluded studies.
Author, Year Reason for exclusion
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Reinhold J., 2015 Not a systematic review
Shahar B., 2014 Not a systematic review
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